New gene therapy platform uses brain fluid pathways to target glial cells
A novel delivery method leverages the glymphatic system to transport genetic material to glial cells, bypassing the blood-brain barrier. This approach aims to reduce systemic toxicity while providing a method for treating neurodegenerative conditions.
A new gene therapy delivery platform, developed by researchers at the University of Rochester Medical Center, utilizes the brain’s own fluid transport networks to bypass the blood-brain barrier. This development provides a method to deliver genetic material throughout the brain while preferentially targeting human glial cells. By engineering specialized viral vectors to travel via the glymphatic system, the researchers aim to overcome hurdles in neurology regarding systemic toxicity and the difficulty of reaching targets behind the blood-brain barrier.
Targeting Glial Cells
The research emphasizes the role of glial cells, which include astrocytes and oligodendrocytes. While historically overshadowed by studies focused on neurons, glial dysfunction is recognized as a key driver in conditions such as multiple sclerosis, Huntington's disease, and pediatric white matter disorders. Steve Goldman, co-director of the University of Rochester Medicine Center for Translational Neuromedicine, noted that human glial progenitor cells can be used to replace diseased cells, making them a primary target for this genetic approach. The team screened a library of modified adeno-associated virus (AAV) 5 viral vectors in mice previously transplanted with human glial progenitor cells. This selection process allowed researchers to identify viral capsids that specifically infect human glia in a living brain environment, a departure from standard models that rely on cell cultures or non-human tissues.
Media additions
Glymphatic Delivery Route
The platform pairs these engineered AAVs with a delivery strategy that harnesses the brain's natural fluid transport pathways. Developed alongside neuroscientist Maiken Nedergaard, the method involves injecting the engineered viruses into the cisterna magna — a fluid-filled space at the base of the brain — and using hypertonic treatment to enhance the uptake of these vectors into the brain's glymphatic pathways. This system circulates cerebrospinal fluid to clear metabolic waste, allowing the therapeutic vectors to spread broadly through brain tissue while minimizing exposure to peripheral organs such as the liver, which is a common source of toxicity in systemic therapies.
Broad Precision Neuroscience
This advancement arrives alongside a surge in genetic research. Multiple research teams funded by the National Institutes of Health (NIH) have recently published findings regarding new gene delivery toolkits. These toolkits provide scientists with computer programs powered by artificial intelligence that identify genetic switches, or enhancers, necessary to target specific cell types in the brain and spinal cord. According to John Ngai, Director of the NIH’s BRAIN Initiative, the goal is to gain granular access to specific cell neighborhoods. While the Rochester team focuses on the glymphatic delivery route for glial disorders, the broader toolkit, now available via distributors like Addgene, seeks to provide standardized procedures for researchers studying diverse conditions ranging from seizure disorders to Parkinson's disease.
Comparative Delivery Strategies
The field is currently exploring several methods to improve therapeutic access to the central nervous system:
| Strategy | Mechanism | Primary Goal |
|---|---|---|
| Glymphatic Transport | Harnesses natural fluid circulation via the cisterna magna | Broad, brain-wide distribution for glial targeting |
| Receptor-Mediated Transcytosis | Capsids engineered to bind receptors like TfR1 | Overcoming blood-brain barrier via bloodstream |
What to Watch Next
- Clinical Transition: Researchers are exploring the use of artificial intelligence to design future viral capsids, which may tailor therapies to specific diseases.
- Platform Scalability: The Rochester team aims to expand this framework to cover a variety of neurodegenerative disorders where glial support is compromised, including pediatric lysosomal storage diseases.
While current therapies have historically managed symptoms, these new platforms aim to shift the therapeutic paradigm toward direct genetic modification. As research progresses, the ability to combine high-precision viral vectors with the brain’s own physiological pathways is expected to provide a new, more efficient route for treating previously intractable neurological conditions.
